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llergic Reactions
fter the Implantation
f Drug-Eluting Stents
s it the Pill or the Polymer?*
abak Azarbal, MD,
esse W. Currier, MD, FACC
os Angeles, California
rug-eluting stents (DES) have been demonstrated to
ecrease clinical and angiographic restenosis rates compared
o bare-metal stents (1,2). Their use continues to increase
nd now accounts for75% of all stents utilized; more than
,000,000 DES have been implanted in the U.S. to date
3,4). In this issue of the Journal, Nebeker et al. (5) report on
ypersensitivity cases associated with implantation of DES
rom the Research on Adverse Drug/Device Events and
eports (RADAR) (6). Despite several important limita-
ions including those inherent to the analysis of post-
arketing surveillance data, the report represents the largest
nd most ambitious analysis of hypersensitivity reactions to
ES published. A concerted attempt has been made to
elineate the cause, clinical course, and sequelae of hyper-
ensitivity reactions after DES implantation.
See page 175
Data for the study were obtained from the Food and
rug Administration’s (FDA) Manufacturer and User De-
ice Experience Center (MAUDE) (7), but the authors also
tilized data obtained from a review of electronic databases
nd their own clinical practice. A total of 262 cases of
ypersensitivity reactions associated with DES implantation
ere evaluated to assess the etiology as well as the severity.
On the basis of available information, 17 of 262 cases (14
YPHER [Cordis Corp., Miami Lakes, Florida] and 3
AXUS [Boston Scientific Corp., Natick, Massachusetts])
ere classified as probably or certainly caused by the stent
mplantation. Four autopsies in patients who died of coro-
ary thrombosis confirmed intrastent eosinophilic inflam-
ation, thrombosis, and lack of intimal healing; 13 cases
ere classified as “probably” having a hypersensitivity reac-
ion to DES (8). Clinical manifestations were primarily
utaneous, usually beginning within 10 days of stent im-
lantation. Symptom duration was 4 weeks in 11 of 17
atients.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theo
merican College of Cardiology.
From the David Geffen School of Medicine at UCLA, Los Angeles, California.Based on the findings of the autopsy studies, one can
onclude that hypersensitivity to DES is a real entity. The
uthors have shown that when present, hypersensitivity
eactions after DES can result in serious clinical sequelae,
ncluding need for hospitalization (18%), emergent inter-
entions such as intravenous steroids or repeat catheteriza-
ion (34%), or death (2%). However, determination of the
ncidence and overall clinical significance of hypersensitivity
eactions after DES implantation is more problematic.
There are several important limitations of this study,
ncluding those pertaining to the use of the FDA’s
AUDE center. First, the true incidence of the event
annot be reliably estimated. These events are primarily
elf-reported either by the manufacturer or health care
ersonnel. While adverse post-marketing events are gener-
lly underreported to the FDA (9), the magnitude of
nderreporting is unknown for any given device or medica-
ion. Adverse event reports require only the suspicion of a
elationship to the device or medication and do not imply
ausality. The clinical information may be incomplete in
any instances. In the study, concomitant medications were
ot reported 40% of the time, and the de-challenge response
o medications was not reported in 81% of cases. Although
he authors made an attempt to ascertain the cause of the
ypersensitivity reaction, an unequivocal cause and effect
ould be proven in only four cases.
Finally, the denominator is unknown. Although the
umber of stents implanted is available, the exact number of
atients who have undergone DES implantation is un-
nown. However, even assuming two DES are placed per
atient, the incidence would still be extremely low (0.002%).
Nevertheless, post-marketing analysis of adverse events
as many advantages. Pre-marketing clinical trials typical
nroll 5,000 patients and are not powered to detect rare
dverse events (10); post-marketing analysis can detect these
are events (11). Also, after marketing, many medications
nd devices are used in a broader, higher-risk population
hat was not included in the pre-marketing studies. Post-
arketing adverse event reporting has contributed to the
ithdrawal of several medications (12).
In patients with documented hypersensitivity reactions
fter DES implantation, the reaction could be due either to
edical therapy associated with stent implantation or to the
ES itself. Several components of the DES could be
esponsible for the hypersensitivity reaction. These include
he polymer coating, the drug (rapamycin for CYPHER
nd paclitaxel for TAXUS), or the stent itself. The use of
are-metal stents has not been associated with hypersensi-
ivity reactions. A series of 400 autopsies revealed no
vidence of hypersensitivity reactions to the bare-metal stent
13). Drug reactions to rapamycin are extremely uncommon
14). Paclitaxel has been associated with hypersensitivity
eactions, but many of these reactions have been attributed
o the castor oil vehicle (15). Thus, the most likely etiology
f the hypersensitivity reaction is the polymer coating of the
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January 3, 2006:182–3 Editorial CommentES. Related synthetic polymers, when applied to bare-
etal stents, have demonstrated both local and systemic
ypersensitivity responses after implantation in one animal
tudy (16).
Patients with known coronary artery disease who have
ndergone implantation of DES typically require multiple
edications. Determining the cause of a hypersensitivity
eaction is often confounded by the potential for hypersen-
itivity to concomitant medications. Of particular impor-
ance for the clinician is the hypersensitivity reaction to the
ommonly prescribed thienopyridine antiplatelet agent clo-
idogrel, which occurs in 5% of patients (14). The most
ommon presentation is rash; more serious hypersensitivity
eactions requiring treatment with corticosteroids are rare
17). Clopidogrel desensitization has been accomplished
uccessfully in one case report and is an option in patients
ith prior reactions (18). Alternatively, one could utilize
iclopidine. However, use of ticlopidine is associated with
igher rates of adverse reactions, including thrombotic
hrombocytopenic purpura and neutropenia.
It is important to not terminate thienopyridine therapy
arly after stent implantation in patients with a suspected
ypersensitivity reaction as this has been associated with
tent thrombosis (19,20). In a recent study, stent thrombosis
ccurred in 29% of patients in whom antiplatelet therapy
as prematurely discontinued (20). On the other hand,
ontinuation of the offending agent in the presence of a
erious allergic reaction can also be dangerous.
In summary, hypersensitivity to DES is a real entity and
an result in serious clinical sequelae including stent throm-
osis and death. While the exact incidence is unknown, it
ppears to be extremely low based on available data. Clini-
ians should be familiar with the clinical presentation of
hese hypersensitivity reactions, and any suspected patient
ith a potential hypersensitivity reaction after DES implan-
ation should be evaluated thoroughly and monitored close-
y; failure to do so can result in serious clinical consequences.
ontinued surveillance of hypersensitivity reactions after
ES implantation is an important process and should
urther enhance our current understanding of this entity.
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ivision of Cardiology, David Geffen School of Medicine at
CLA, CHS 47-123, Box 951679, 10833 Le Conte Avenue, Los
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